AcceleRET-Lung
Phase 3 Terminated
223 enrolled 18 charts
KEYVIBE-001
Phase 1 Completed
474 enrolled 39 charts
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
68 enrolled 27 charts
The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy
Phase NA Terminated
1 enrolled 6 charts
AUREA
Phase 2 Completed
82 enrolled 20 charts
EURTAC
Phase 3 Completed
174 enrolled 20 charts
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Phase 1/2 Completed
48 enrolled 24 charts
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
Phase 1 Completed
829 enrolled 100 charts
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Phase 1/2 Completed
68 enrolled 13 charts
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Phase 2 Completed
229 enrolled 14 charts
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
Phase 1 Completed
110 enrolled 80 charts
MK-3475-434
Phase 1 Completed
34 enrolled 25 charts
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Phase 2 Terminated
137 enrolled 9 charts
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
Phase 1 Completed
53 enrolled 20 charts
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Phase 1 Completed
60 enrolled 15 charts
EPIC
Phase 2 Completed
110 enrolled 14 charts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Phase 2 Completed
54 enrolled 7 charts
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Phase 1 Completed
65 enrolled 32 charts
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Phase 1/2 Terminated
15 enrolled 11 charts
A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before
Phase 2 Completed
64 enrolled 20 charts
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
Phase 2 Completed
39 enrolled 10 charts
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer
Phase 1/2 Terminated
7 enrolled 8 charts
Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
Phase 2 Terminated
6 enrolled 4 charts
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
152 enrolled 18 charts
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
172 enrolled 13 charts
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Phase 3 Completed
319 enrolled 7 charts
UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy
Phase 3 Completed
668 enrolled 7 charts
BALI-1
Phase 2 Completed
181 enrolled 15 charts
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 Completed
63 enrolled 15 charts
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Phase 1 Completed
102 enrolled 48 charts